Rising rates of obesity and overweight affect millions. Rochester Clinical Research is conducting a research study to evaluate the safety and effectiveness of a once-weekly investigational medication (eloralinitide) compared with placebo for weight loss.
If you participate in the research study, your participation will last approximately 18 months for those without prediabetes with 14 visits to our office in addition to 2 visits for blood draw only and 6 telephone call visits. For those with prediabetes diagnosed at the start of the study, it will last approximately 44 months with about 25 visits to our office in addition to 2 blood draw only visits and about 14 telephone call visits. There is a 22% chance you will receive placebo. There is no cost to participate, and if you qualify, you may be compensated for time and travel.
To learn more, or to see if you qualify, please fill out the form below.
Adults 18 and older with obstructive sleep apnea (OSA) and overweight or obesity may qualify for a clinical study evaluating […]
Rochester Clinical Research is seeking adults to participate in a research study evaluating an investigational medication for nerve pain caused […]
Adults 65 years and older may qualify for a study evaluating an investigational vaccine designed to help prevent C. difficile […]
Rochester Clinical Research is enrolling healthy adults ages 50–64 for a COVID-19 vaccine research study (non-mRNA). This study is enrolling […]
Rochester Clinical Research is currently enrolling adults for a research study evaluating a once-weekly injection for people with knee pain […]
Adults 18 to 80 years of age may qualify for a study evaluating an investigational treatment for irritable bowel syndrome […]
